This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Pharma firms lean on US trademark law to halt weight loss drug counterfeits

By Nick Robertson ( April 16, 2025, 19:06 GMT | Comment) -- Drug companies are increasingly turning to the Lanham Act in the US to stop the distribution of GLP-1 weight loss medications by compounding pharmacies. Industry leaders say compounded drugs sold as Ozempic, Wegovy and Mounjaro are not only unsafe for consumers, but also infringing intellectual property rights. While other countries, including Australia and South Africa, move to curb the practice, American legislators haven’t yet taken the same steps.Novo Nordisk and Eli Lilly & Co., manufacturers of leading weight loss medications, are increasingly using US trademark law to stop counterfeits from compounding pharmacies. The companies have filed dozens of suits under the Lanham Act since 2023 to stop sellers from labeling compounded drugs as their own medications....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections